Rein Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 0.7266 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 62.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs ...